Interdisciplinary cancer research, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 7, 2025
The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy targeted treatments. Immunotherapies like pembrolizumab, nivolumab, ipilimumab pioneered new avenues, potentially improving patient outcomes quality life. Additionally, advances immunotherapy prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing hope for patients shaping future practice. This review delves the mechanisms various evaluates their therapeutic potential when combined radiotherapy, chemotherapy, clinical settings. It also sheds light on current application involving treatment.
Language: Английский
Citations
2
Seminars in Cancer Biology, Journal Year: 2024, Volume and Issue: 104-105, P. 1 - 15
Published: July 18, 2024
Language: Английский
Citations
10
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: Jan. 2, 2025
As immune-checkpoint inhibitors (ICIs) therapy has made great strides in hepatocellular carcinoma (HCC) treatment, improving patient response to this strategy become the main focus of research. Accumulating evidence shown that m6A methylation plays a crucial role tumorigenesis and progression HCC, while precise impact demethylase ALKBH5 on tumor immune microenvironment (TIME) HCC remains poorly defined. The clinical significance TIM3 were evaluated human tissues. biological function was analyzed vitro vivo. molecular subtypes identified based key ALKBH5-regulated methylation-related genes (MRGs). differences survival, features, TIME immunotherapy between these two then evaluated. regulation detected by qPCR, western blotting MeRIP. downregulated associated with worse prognosis. inhibited proliferation migration activities cells subtype high expression MRGs characterized immunosuppression phenotypes ICIs. Moreover, as target ALKBH5. Upregulated level negatively correlated survival HCC. results study suggest is an important regulator progression. exerts its influence targeting This work provides new insight into correlation modification ICI response, which may help provide therapeutic benefits patients.
Language: Английский
Citations
1
Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 906 - 906
Published: March 6, 2025
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immunotherapy targeting the PD-1/PD-L1 axis has revolutionized treatment, providing durable responses in subset patients. However, with fewer than 50% patients achieving significant benefits, there is critical need to expand therapeutic strategies. This review explores emerging targets immune checkpoint inhibition beyond PD-1/PD-L1, including CTLA-4, TIGIT, LAG-3, TIM-3, NKG2A, and CD39/CD73. We highlight biological basis CD8 T cell exhaustion shaping antitumor response. Novel approaches additional inhibitory receptors (IR) are discussed, focus on their distinct mechanisms action combinatory potential existing therapies. Despite advancements, challenges remain overcoming resistance optimizing patient selection. underscores importance dual blockade innovative bispecific antibody engineering maximize outcomes for NSCLC
Language: Английский
Citations
1
Pharmacological Research, Journal Year: 2024, Volume and Issue: 209, P. 107458 - 107458
Published: Oct. 11, 2024
Numerous preclinical studies have demonstrated the inhibitory function of T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) on cells as an receptor, leading to clinical development anti-Tim-3 blocking antibodies. However, recent shown that Tim-3 is expressed not only but also multiple types in tumor microenvironment (TME), including dendritic (DCs), natural killer (NK) cells, macrophages, and cells. Therefore, blockade immune affect influence functions other For example, can enhance ability DCs regulate innate adaptive immunity. The role NK controversial, it antitumor under certain conditions while having opposite effect situations. Additionally, promote reversal macrophage polarization from M2 phenotype M1 phenotype. Furthermore, inhibit by suppressing proliferation metastasis In summary, increasing evidence has plays a critical efficacy therapy. Understanding therapy non-T help elucidate diverse responses observed patients, better relevant therapeutic strategies. This review aims discuss TME emphasize impact beyond
Language: Английский
Citations
6
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Sept. 20, 2024
A steady dysfunctional state caused by chronic antigen stimulation in the tumor microenvironment (TME) is known as CD8 + T cell exhaustion. Exhausted-like cells (CD8 Tex) displayed decreased effector and proliferative capabilities, elevated co-inhibitory receptor generation, cytotoxicity, changes metabolism transcription. TME induces exhaustion through long-term stimulation, upregulation of immune checkpoints, recruitment immunosuppressive cells, secretion cytokines. Tex may be both reflection cancer progression reason for poor control. The successful outcome current immunotherapies, which include checkpoint blockade adoptive treatment, depends on Tex. In this review, we are interested intercellular signaling network interacting with These findings provide a unique detailed perspective, helpful changing completely unpopular hypofunction intensifying effect immunotherapy.
Language: Английский
Citations
4
European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 283, P. 117141 - 117141
Published: Dec. 5, 2024
Language: Английский
Citations
4
Cells, Journal Year: 2025, Volume and Issue: 14(5), P. 346 - 346
Published: Feb. 27, 2025
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression. Rigorous investigation over the last decade has elucidated TIM-3 as a key player inhibiting activation several associated molecules identified both upstream downstream that mediate dysfunction mechanistically. However, despite reviews being published on other such PD-1 CTLA-4 setting, no extensive review exists specifically focuses role of progression immunosuppression. Here, we critically summarize current literature regarding expression prognostic marker for glioblastoma, its profile cells patients exploration anti-TIM-3 agents pre-clinical models potential clinical application.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 18, 2025
Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Immunotherapy has emerged as promising approach, yet its efficacy in osteosarcoma is hindered by an immunosuppressive tumor microenvironment and resistance mechanisms. This review explores recent advancements checkpoint blockade, cellular therapies, combination strategies aimed at enhancing immune responses. We highlight key challenges, including heterogeneity, poor infiltration, the need for predictive biomarkers. By integrating immunotherapy chemotherapy, radiotherapy, targeted therapy, emerging approaches seek to improve outcomes. provides comprehensive analysis of evolving landscape immunotherapy, offering insights into future directions potential breakthroughs. Researchers clinicians will benefit from understanding these developments, they pave way more effective personalized osteosarcoma.
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4332 - 4332
Published: May 2, 2025
Various inhibitors targeting T-cell immunoglobulin and mucin-containing molecule 3 (TIM3) aimed at reversing exhaustion for better immunotherapy outcomes have demonstrated limited clinical efficacy as monotherapy, with the underlying mechanisms remaining ambiguous. TIM3 is markedly expressed in dendritic cells (DCs), inconsistent research findings on its role myeloid underscore vital function within DCs. Through establishment of an vitro differentiation model generating mature (mDCs) under TIM3-targeted interventions, combined RNA sequencing analysis, this investigation systematically examined TIM3-mediated regulation ligand interactions human primary The indicate that inhibition hinders DC maturation, which subsequently diminishes antigen-presenting capacity DCs, ultimately leading to immune suppression T cells. These collectively establish a regulator promotes maturation while optimizing antigen-processing presentation capacity. This study elucidates rationale behind suboptimal advocates retaining signaling pathways
Language: Английский
Citations
0